The DOI matches its Crossref record, with a small difference in title or year; 6 of the 6 references it cites were found in a registry or an index.
COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“COTI-2 inhibits tumor growth in a p53-dependent and p53-independent manner, ultimately leading to cell cycle arrest and apoptosis.448–450”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [448]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
Research works printed but not linked: 38
- Workman, 2012, Discovery of small molecule cancer drugs: successes, challenges and opportunities, Molecular oncology, 6, 155, 10.1016/j.molonc.2012.02.004 · DOI · Paper page
- Walensky, 2007, The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members, Clinical cancer research, 13, 7264, 10.1158/1078-0432.CCR-07-2184 · DOI · Paper page
- Lowe, 2014, Computational methods in drug discovery, Pharmacological reviews, 66, 334, 10.1124/pr.112.007336 · DOI · Paper page
- Shapiro, 2003, Virtual screening to enrich hit lists from high-throughput screening: a case study on small-molecule inhibitors of angiogenin, Proteins, 50, 81, 10.1002/prot.10270 · DOI
- Di Giovanni, 2013, Virtual screening strategies in drug discovery: a critical review, Current medicinal chemistry, 20, 2839, 10.2174/09298673113209990001 · DOI · Paper page
- Gerber, 2008, Targeted therapies: a new generation of cancer treatments, American family physician, 77, 311
- Kirkpatrick, 2004, Cetuximab, Nature reviews Drug discovery, 3, 549, 10.1038/nrd1445 · DOI
- Gridelli, 2014, Cetuximab in advanced non-small cell lung cancer (NSCLC): the showdown?, Journal of thoracic disease, 6, 578
- Occelli, 2007, Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck, Therapeutics and clinical risk management, 3, 871
- Ko, 2008, Erlotinib in the treatment of advanced pancreatic cancer, Biologics, 2, 83
- Thatcher, 2005, Erlotinib in non-small cell lung cancer: a review, Expert opinion on pharmacotherapy, 6, 995, 10.1517/14656566.6.6.995 · DOI
- Coleman, 1991, Chemotherapy for glioblastoma multiforme, The Journal of neuroscience nursing, 23, 68, 10.1097/01376517-199102000-00014 · doi:10.1097/01376517-199102000-00014
- Salmaggi, 2009, Cisplatinum and BCNU chemotherapy in primary glioblastoma patients, Journal of neuro-oncology, 94, 57, 10.1007/s11060-009-9800-0 · doi:10.1007/s11060-009-9800-0
- Slingluff, 2009, Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2, Cancer immunology, immunotherapy, 58, 867, 10.1007/s00262-008-0602-6 · DOI
- Festjens, 2006, Caspase inhibitors promote alternative cell death pathways, Science's STKE, 2006, pe44
- Brady, 2008, PI3K/AKT inhibition induces caspase-dependent apoptosis in HTLV-1-transformed cells, Virology, 370, 264, 10.1016/j.virol.2007.09.003 · DOI
- Rehm, 2012, The central role of initiator caspase-9 in apoptosis signal transduction and the regulation of its activation and activity on the apoptosome, Experimental cell research, 318, 1213, 10.1016/j.yexcr.2012.02.013 · DOI · Paper page
- Yamakawa, 2002, Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma, Cancer, 94, 3127, 10.1002/cncr.10591 · DOI · Paper page
- Pavlidis, 2012, Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management, Annals of gastroenterology, 25, 106
- Bramson, 2011, Defining the critical hurdles in cancer immunotherapy, Journal of translational medicine, 9, 214, 10.1186/1479-5876-9-214 · DOI
- Reynolds, 2014, Combining computational methods for hit to lead optimization in Mycobacterium tuberculosis drug discovery, Pharmaceutical research, 31, 414, 10.1007/s11095-013-1172-7 · DOI
- Swanton, 2015, Biological and therapeutic impact of intratumor heterogeneity in cancer evolution, Cancer cell, 27, 15, 10.1016/j.ccell.2014.12.001 · DOI · Paper page
- Meltzer, 2003, Gene expression profiles in a panel of childhood leukemia cell lines mirror critical features of the disease, Molecular cancer therapeutics, 2, 671
- Murgo, 2006, Drug development in oncology: classical cytotoxics and molecularly targeted agents, British journal of clinical pharmacology, 62, 15, 10.1111/j.1365-2125.2006.02713.x · DOI · Paper page
- Rafii, 2002, VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition, Blood, 99, 2532, 10.1182/blood.V99.7.2532 · DOI · Paper page
- Geng, 2014, Molecularly targeted cancer therapy: some lessons from the past decade, Trends in pharmacological sciences, 35, 41, 10.1016/j.tips.2013.11.004 · DOI · Paper page
- Gridelli, 2014, Irreversible EGFR inhibitors in the treatment of advanced NSCLC, Current pharmaceutical design, 20, 3894, 10.2174/13816128113196660764 · DOI
- Garrone, 2007, Treatment of advanced head and neck cancer with cetuximab, The International journal of biological markers, 22, S71, 10.1177/17246008070221s409 · doi:10.1177/17246008070221s409
- DeAngelis, 2013, Glioblastoma and other malignant gliomas: a clinical review, Jama, 310, 1842, 10.1001/jama.2013.280319 · DOI · Paper page
- Friedman, 2007, Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas, Therapeutics and clinical risk management, 3, 707
- Bodmer, 2010, Cancer stem cells from colorectal cancer-derived cell lines, Proceedings of the National Academy of Sciences of the United States of America, 107, 3722, 10.1073/pnas.0915135107 · DOI · Paper page
- Pantos, 2011, Cell-type-dependent thyroid hormone effects on glioma tumor cell lines, Journal of thyroid research, 2011, 856050
- Horwitz, 1994, Taxol (paclitaxel): mechanisms of action, Annals of oncology, 5, S3
- Koropatnick, 2015, IDO Downregulation Induces Sensitivity to Pemetrexed, Gemcitabine, FK866, and Methoxyamine in Human Cancer Cells, PloS one, 10, e0143435, 10.1371/journal.pone.0143435 · DOI
- Gray, 2011, High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors, Chemistry & biology, 18, 868, 10.1016/j.chembiol.2011.05.010 · DOI
- Horiuchi, 2008, The challenge of selecting protein kinase assays for lead discovery optimization, Expert opinion on drug discovery, 3, 607, 10.1517/17460441.3.6.607 · DOI · Paper page
- Potier, 1988, Antineoplastic activity of two taxol derivatives on an ovarian tumor xenografted into nude mice, Anticancer research, 8, 387
- Howell, 1990, Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma, Cancer communications, 2, 93, 10.3727/095535490820874641 · DOI
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Targeting mutant p53 for efficient cancer therapy
Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.109 · Cited by 889
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517
TP53 Mutation in Acute Myeloid Leukemia: An Old Foe Revisited
Shin, D.-Y. (2023) · Cancers · doi:10.3390/cancers15194816 · Cited by 46
Small-molecule correctors and stabilizers to target p53
Fallatah, M. M. J., Law, F. V., Chow, W. A., & Kaiser, P. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.02.007 · Cited by 44
Metadata
- Authors
- Salim, K. Y., Maleki Vareki, S., Danter, W. R., San-Marina, S., & Koropatnick, J.
- Affiliations
- Critical Outcome Technologies Inc., London, Ontario, Canada
- Cancer Research Laboratory Program, Lawson Health Research Institute, London, Ontario, Canada
- Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic School of Medicine, Rochester, Minnesota, USA
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-05-02
- Volume
- 7
- Issue
- 27
- Pages
- 41363-41379
- ISSN
- 1949-2553
- Cited by
- 148
- References
- 6
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo. https://app.cochat.ai/papers/10.18632/oncotarget.9133
- The paper
- Salim, K. Y., Maleki Vareki, S., Danter, W. R., San-Marina, S., & Koropatnick, J. (2106). COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo. Oncotarget. https://doi.org/10.18632/oncotarget.9133
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
